134 related articles for article (PubMed ID: 37523582)
21. New respiratory syncytial virus immunization products in low- and middle-income countries: potential for cost-effective impact on a high burden of disease in young infants.
Srikantiah P; Klugman KP
BMC Med; 2023 May; 21(1):177. PubMed ID: 37183242
[TBL] [Abstract][Full Text] [Related]
22. Preparation and Evaluation of the Fully Humanized Monoclonal Antibody GD-mAb Against Respiratory Syncytial Virus.
Tian P; Wang Y; Liu H; Yang Y; Wu X; Wei H; Chen T
Front Cell Infect Microbiol; 2019; 9():275. PubMed ID: 31417879
[TBL] [Abstract][Full Text] [Related]
23. Differential diagnoses of influenza A virus, influenza B virus, and respiratory syncytial virus infections by direct immunofluorescence using mixtures of monoclonal antibodies of different isotypes.
Murphy P; Roberts ZM; Waner JL
J Clin Microbiol; 1996 Jul; 34(7):1798-800. PubMed ID: 8784593
[TBL] [Abstract][Full Text] [Related]
24. Production and characterization of monoclonal antibodies to bovine respiratory syncytial virus.
Underwood WJ; McCallum Q; Velicer LF; Mufson MA; Baker JC
Vet Microbiol; 1995 Feb; 43(2-3):261-74. PubMed ID: 7740764
[TBL] [Abstract][Full Text] [Related]
25. Association of Respiratory Syncytial Virus Infection and Underlying Risk Factors for Death Among Young Infants Who Died at University Teaching Hospital, Lusaka Zambia.
Forman LS; Macleod W; Mwananyanda L; Kwenda G; Pieciak R; Mupila Z; Murphy C; Thea D; Chikoti C; Yankonde B; Ngoma B; Chimoga C; Gill CJ
Clin Infect Dis; 2021 Sep; 73(Suppl_3):S180-S186. PubMed ID: 34472569
[TBL] [Abstract][Full Text] [Related]
26. Respiratory syncytial virus fusion nanoparticle vaccine immune responses target multiple neutralizing epitopes that contribute to protection against wild-type and palivizumab-resistant mutant virus challenge.
Gilbert BE; Patel N; Lu H; Liu Y; Guebre-Xabier M; Piedra PA; Glenn G; Ellingsworth L; Smith G
Vaccine; 2018 Dec; 36(52):8069-8078. PubMed ID: 30389195
[TBL] [Abstract][Full Text] [Related]
27. Immunoprophylaxis with palivizumab, a humanized respiratory syncytial virus monoclonal antibody, for prevention of respiratory syncytial virus infection in high risk infants: a consensus opinion.
Meissner HC; Welliver RC; Chartrand SA; Law BJ; Weisman LE; Dorkin HL; Rodriguez WJ
Pediatr Infect Dis J; 1999 Mar; 18(3):223-31. PubMed ID: 10093942
[No Abstract] [Full Text] [Related]
28. Palivizumab in the prophylaxis of respiratory syncytial virus infection.
Cardenas S; Auais A; Piedimonte G
Expert Rev Anti Infect Ther; 2005 Oct; 3(5):719-26. PubMed ID: 16207163
[TBL] [Abstract][Full Text] [Related]
29. Respiratory Syncytial Virus and Human Metapneumovirus Infections in Three-Dimensional Human Airway Tissues Expose an Interesting Dichotomy in Viral Replication, Spread, and Inhibition by Neutralizing Antibodies.
Kinder JT; Moncman CL; Barrett C; Jin H; Kallewaard N; Dutch RE
J Virol; 2020 Sep; 94(20):. PubMed ID: 32759319
[TBL] [Abstract][Full Text] [Related]
30. Safety of palivizumab in preterm infants 29 to 32 weeks' gestational age without chronic lung disease to prevent serious respiratory syncytial virus infection.
Groothuis JR
Eur J Clin Microbiol Infect Dis; 2003 Jul; 22(7):414-7. PubMed ID: 12827537
[TBL] [Abstract][Full Text] [Related]
31. Prevention of respiratory syncytial virus infections.
Bricks LF
Rev Hosp Clin Fac Med Sao Paulo; 2001; 56(3):79-90. PubMed ID: 11514908
[TBL] [Abstract][Full Text] [Related]
32. Respiratory syncytial virus detection by immunofluorescence in nasal secretions with monoclonal antibodies against selected surface and internal proteins.
Kim HW; Wyatt RG; Fernie BF; Brandt CD; Arrobio JO; Jeffries BC; Parrott RH
J Clin Microbiol; 1983 Dec; 18(6):1399-404. PubMed ID: 6361054
[TBL] [Abstract][Full Text] [Related]
33. Cost-effectiveness of Respiratory Syncytial Virus Disease Prevention Strategies: Maternal Vaccine Versus Seasonal or Year-Round Monoclonal Antibody Program in Norwegian Children.
Li X; Bilcke J; Vázquez Fernández L; Bont L; Willem L; Wisløff T; Jit M; Beutels P;
J Infect Dis; 2022 Aug; 226(Suppl 1):S95-S101. PubMed ID: 35292816
[TBL] [Abstract][Full Text] [Related]
34. How Viral Sequence Analysis May Guide Development of Respiratory Syncytial Virus Monoclonal Antibodies.
Langedijk AC; Bont LJ
Clin Infect Dis; 2021 Dec; 73(11):e4409-e4410. PubMed ID: 32640025
[No Abstract] [Full Text] [Related]
35. Effects of anti-g and anti-f antibodies on airway function after respiratory syncytial virus infection.
Han J; Takeda K; Wang M; Zeng W; Jia Y; Shiraishi Y; Okamoto M; Dakhama A; Gelfand EW
Am J Respir Cell Mol Biol; 2014 Jul; 51(1):143-54. PubMed ID: 24521403
[TBL] [Abstract][Full Text] [Related]
36. The secreted form of respiratory syncytial virus G glycoprotein helps the virus evade antibody-mediated restriction of replication by acting as an antigen decoy and through effects on Fc receptor-bearing leukocytes.
Bukreyev A; Yang L; Fricke J; Cheng L; Ward JM; Murphy BR; Collins PL
J Virol; 2008 Dec; 82(24):12191-204. PubMed ID: 18842713
[TBL] [Abstract][Full Text] [Related]
37. Preparation and characterization of monoclonal antibodies directed against five structural components of human respiratory syncytial virus subgroup B.
Orvell C; Norrby E; Mufson MA
J Gen Virol; 1987 Dec; 68 ( Pt 12)():3125-35. PubMed ID: 2447224
[TBL] [Abstract][Full Text] [Related]
38. [Development and properties of neutralizing monoclonal antibodies for fusion protein of respiratory syncytial virus.].
Kushch AA; Klimova RR; Fedorova NE; Masalova OV; Niconova AA; Lesnova EI; Momotyuk ED; Demidova NA; Samartseva TG; Zverev VV
Vopr Virusol; 2019; 64(2):90-96. PubMed ID: 31412175
[TBL] [Abstract][Full Text] [Related]
39. Development of Human Monoclonal Antibodies Against Respiratory Syncytial Virus Using a High Efficiency Human Hybridoma Technique.
Alvarado G; Crowe JE
Methods Mol Biol; 2016; 1442():63-76. PubMed ID: 27464688
[TBL] [Abstract][Full Text] [Related]
40. Monoclonal antibodies for the rapid diagnosis of respiratory syncytial virus infection by immunofluorescence.
Kao CL; McIntosh K; Fernie B; Talis A; Pierik L; Anderson L
Diagn Microbiol Infect Dis; 1984 Jun; 2(3):199-206. PubMed ID: 6204807
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
